A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53‐null mammary epithelial cell mode .
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Approximately 40% of human breast cancers contain alterations in the tumor suppressor p53. The p53 172R‐H gain‐of‐function mutant (equivalent to the common 175R‐H human breast cancer mutant) has been shown to promote aneuploidy and tumorigenesis in the mammary gland in transgenic mice and may affect genomic stability in part by causing centrosome abnormalities. The precise mechanism of action of these gain‐of‐function mutants is not well understood. and has been studied primarily in fibroblast cell lines. A novel p53‐null mouse mammary epithelial cell line developed from p53‐null mice has been used in adenovirus‐mediated transient transfection experiments to study the properties of this p53 mutant. Marked centrosome amplification and an increased frequency of aberrant mitoses were observed within 72 h of introduction of p53 172R‐H. However. few cells with aberrant centrosome numbers were observed in cells stably expressing the p53 172R‐H mutant. Furthermore. stable expression of this p53 mutant reduced both basal and DNA damage‐induced apoptosis. This result may be mediated in part through abrogation of p73 function. The p53 172R‐H mutant. therefore. appears to influence tumorigenesis at the molecular level in two distinct ways: promoting the development of aneuploidy in cells while also altering their apoptotic response after DNA damage.—Murphy. K. L.. Dennis. A. P.. Rosen. J. M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53‐null mammary epithelial cell model. FASEB J. 14. 2291‐2302 (2000)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 2×
“A p73 Western blot with a COS cell positive control (1) followed by p53 172R-H-expressing stable cells, untreated and irradiated (lanes 1 and 2, respectively) and then untreated and irradiated control cells (lanes 3 and 4, respectively).”
Background
Cited by
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“…Li et al., 1998; Matas et al., 2001; Pohl et al., 1999; Trepel et al., 1998 R175H MEC, 10(3), HEC-50 stable/transient Dong et al., 2012; Murphy et al., 2000; Pugacheva et al., 2002 R175H SK-BR3 endogenous Bossi et al., 2006; Di Agostino et al., 2006; Vaughan et al., 2012b R175H, P223L…”
BackgroundCytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells
Fujiwara, T., Bandi, M., Nitta, M., Ivanova, E. V., Bronson, R. T., & Pellman, D. (2005) · Nature · doi:10.1038/nature04217 · Cited by 1,067
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
“…accumulation It has been previously reported that conformational and DNA contact-defective p53 mutants can increase cellular resistance to chemotherapy or contribute to genome instability (Gualberto et al., 1998; Li et al., 1998; Blandino et al., 1999; Murphy et al., 2000; El-Hizawi et al., 2002).”
BackgroundMolecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 336
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Links between mutant p53 and genomic instability
Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216
“Ectopic expression of mutp53 R172H in p53-null primary mouse mammary epithelial cells resulted in aberrant centrosome amplification, multipolar mitoses, and consequently increased numbers of chromosomes [Murphy et al., 2000].”
BackgroundZalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
“Mutant p53 was also shown to promote genomic instability (Murphy et al., 2000) and to contribute to the disruption of spindle checkpoint control (Gualberto et al., 1998).”
Background
Metadata
- Authors
- Murphy, K. L., Dennis, A. P., & Rosen, J. M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2000-11
- Volume
- 14
- Issue
- 14
- Pages
- 2291-2302
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2024143289
- Cited by
- 92
- References
- 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.